DEMANT Demant A/S

Demant A/S: Managers' transactions

Demant A/S: Managers' transactions

Company announcement no 2020-092 July 2020

Transactions with Demant A/S shares by senior executives and closely related parties

Notification pursuant to article 19, sub-article 2a, of the Market Abuse Regulation:

1.Details of the person discharging managerial responsibilities/person closely associated
a)NameAnja Madsen
2.Reason for the notification
a)Position/statusMember of the Board of Directors
b)Initial notification/amendmentInitial notification
3)Details of the issuer, emission allowance market participant, auction platform, auctioneer

or auction monitor
a)NameDemant A/S
b)LEI213800RM6L9LN78BVA56
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial

instrument, type of instrument



 



Identication code
Shares



 



 



DK0060738599
b)Nature of the transactionPurchase
c)Price(s) and volume(s)Price  Volume

DKK 176.20  751 shares

DKK 176.00  100 shares
d)Aggregated information:

- Aggregated volume

- Price
 



851 shares

DKK 176.37
e)Date of the transaction29 June 2020
f)Place of the transactionNasdaq Copenhagen A/S

* * * * * * *

Further information:

Christian Lange, Investor Relations Officer

Trine Kromann-Mikkelsen, VP Corporate Communication and Relations

Phone

 

 

Attachment

EN
02/07/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Demant A/S

Rune Majlund Dahl
  • Rune Majlund Dahl

Demant (Buy, TP: DKK400.00) - Improved long-term outlook

At its CMD, Demant updated its long-term outlook. It now targets 8–10% LCY growth (7–10%) including 6–8%-points organic growth and c2%-points M&A growth, and still sees incremental EBIT margin expansion. It expects the hearing-aid market to grow 4–6% p.a. in value (2–5%), as ASP is now guided fairly flat. We are positive on the Sirius-based Oticon Intent launch. We reiterate our BUY, and have raised our target price to DKK400 (375).

Oliver Metzger
  • Oliver Metzger

Demant A/S : Strong performance to continue

>Strong performance to continue - Demant’s Q4 results showed, with an organic growth of 10%, a continuation of the strong performance of previous quarters. On the back of the announced launch of the new hearing aid platform Oticon Intega, we expect that the market share gains in the hearing aid segment will continue also in 2024. Our organic growth forecast for 2024 stands at 7.4% (guidance 4-8%) for the company driven by an expected 8.0% for the hearing aid wholesale...

Martin Marandon-Carlhian ... (+3)
  • Martin Marandon-Carlhian
  • Stephane Houri
  • Thomas Zlowodzki

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 02/06/2024

Today we are adding CRH to the ODDO BHF European Large Caps Convictions List. It is exposed to the US economy, which we believe will continue to outperform the European economy, as borne out by the very robust job creation figures released last Friday. CRH generates 75% of its EBITDA in the 10 fastest-growing US states, and also has positive technical catalysts such as its future inclusion in the S&P TMI and Russell 1000 indices. - ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch